CD8A and neoplasm: PD-1 interacts with its ligand, PD-L1, to reduce the proliferation and survival ability of CD8+ T cells and inhibit their secretion of cytokines, which in turn prevents CD8+ T cells from exerting their immune response, promotes resistance to ICIs, and promotes tumor progression.